April 26, 2016 / 12:52 PM / a year ago

BRIEF-Arch Biopartners' AB569 receives positive opinion from EMA COMP

April 26 (Reuters) - Arch Biopartners Inc

* Arch biopartners' AB569 receives positive opinion from EMA COMP for orphan designation for cystic fibrosis

* Plans to submit an investigational new drug application to FDA for AB569 in second half of 2016

* COMP's positive opinion will be forwarded to EC for final approval of orphan designation, expected to be completed in next few weeks Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below